SRT-1720

SRT-1720 is an experimental small-molecule drug developed as a potent activator of the NAD(+)-dependent histone deacetylase sirtuin subtype SIRT1. It was originally studied by Sirtris Pharmaceuticals. In preclinical animal models, SRT‑1720 has demonstrated the ability to improve insulin sensitivity, lower plasma glucose levels in fat, muscle and liver tissue, and enhance mitochondrial function and oxidative metabolism. It is structurally related to resveratrol but is approximately 1000 times more potent as a SIRT1 activator. In multiple myeloma cell studies, it inhibits growth and induces apoptosis even in cells resistant to conventional therapies such as bortezomib. The compound has also been shown to increase mean lifespan in obese diabetic mice but has not advanced into clinical development for humans[1][2][3][5].

Other names

N-(2-(3-(1-piperazinylmethyl)imidazo(2,1-b)thiazol-6-yl)phenyl)-2-quinoxalinecarboxamide2-quinoxalinecarboxamide, n-(2-(3-(1-piperazinylmethyl)imidazo(2,1-b)thiazol-6-yl)phenyl)